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1. INTRODUCTION
This report is submitted, as required by Chapter 75, Section 43(f), on the activities of the
MassBiologics of the University of Massachusetts Medical School. This is the twenty-first
year of such annual report.
The following sections provide the required information as follows:
Part 2, Prior Fiscal Year (FY 17) Information, as indicated by legislation, describes the patents
and licenses, agreements entered into, status of existing agreements, royalties and other
benefits, and expenditures, current assets and liabilities. This section includes two schedules:
(1) FYI 7 Balance Sheet and (2) FY 17 Statement of Revenues and Expenditures and Other
Charges. Included here is information related to appropriated funds for the prior fiscal year,
as required by the legislation.
Part 3, Financial Plans, presents projected revenues and expenses. A three-year projection is 
included. 
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2. PRIOR FISCAL YEAR (FYl 7) INFORMATION
This section of the report presents the specific information indicated in the legislation related
to the prior fiscal year (FYl 7: July I, 2016 - June 30, 2017). This is the twenty-first full year
in which MassBiologics has operated within the University of Massachusetts. The effective
date of the transfer to the University of Massachusetts was January 1, 1997.
a. Patents and Licensing
MassBiologics had two patents with claims allowed in FYI 7:
Title: Antibodies Against Clostridium Difficile Toxins and Uses Thereof 
• Norway - Patent No. 340300 Issued March 27, 2017
Title: Anti-SOD I Antibodies and Uses Thereof 
• United States -Patent No. 9,663,586 Issued May 30, 2017
b. Agreements entered into
MassBiologics extended its exclusive distribution agreement with Grifols Worldwide
Operations Ltd. for the distribution of Tetanus and Diphtheria vaccine for a two year term
ending June 30, 2019.
MassBiologics entered into a non-exclusive license agreement with Antagen Pharmaceuticals
Inc. for monoclonal antibodies for the treatment of diphtheria October 1, 2016.
MassBiologics entered into a commercialization agreement with Adimab LLC for the
commercialization of therapeutic ebola antibodies effective May 2, 2017.
MassBiologics entered into a series of research and collaboration agreements as follows:
1) University of Maryland for research into therapeutic antibodies for ETEC,
effective August 8, 2016.
2) University College London, for research into novel treatment for chronic
granulomatous disease effective April 24, 2017.
3) Sixal Inc. for studies into antibody binding effective May 10, 2017.
4) University of Virginia for studies into ETEC, effective July 12, 2017.
MassBiologics' contract development and manufacturing services enjoyed strong growth in 
FYI 7. Highlights include: addition of 4 new clients utilizing services originating in the 
Mattapan Facility; bio manufacturing capacity at Mattapan booked at I 00% capacity through 
December 2018; completion of South Coast Vector Manufacturing Center "VMC" GMP 
manufacturing facility validations and the production of its first lot of cGMP clinical material; 
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a second VMC client was signed, for whom we will be manufacturing commercial supplies of 
a viral vector therapy for an ultra-orphan neurological disease; one hundred new service 
agreements were executed in FY 17 representing $22.2M in sales and generating $15.4M in 
revenue. 
c. Grants and Contracts Awarded
DARPA-A no cost extension was received on Award of $11,411,276 from Defense ADV
Research Projects Agency through December 31, 2017. $4,422,355 of funding was received
in FYI 7.
Gates Foundation - Award of $1,967,060 was received from Bill and Melinda Gates
Foundation effective May 4, 2017 through December 31, 2018. $54,034 of funding was
received in FYI 7.
NIH Contract -Award of $5,328,431 was received from NIH-Nat'l Inst. Of Allergy &
Infectious Disease effective September 29, 2013 through September 28, 2016. $469,889 of
funding was received in FYI 7.
U24 Grant -Award of $8,645,123 was received from NIH-Nat'I Inst. of Allergy & Infectious
Disease effective September 29, 2016 through May 31, 2021. $1,790,832 of funding was
received in FYl 7.
R24 Grant - Award of $2,837,738 was received from National Institutes of Health effective
January 1, 2016 through November 30, 2019. $545,126 of funding was received in FYI 7.
NIH Grant - A no cost extension was received on Award of $1,160,228 from NIH-Nat'l Inst.
of Allergy & Infectious Disease through April 30, 2018. An additional Award of $56,133
was received. $302,997 of funding was received in FYI 7.
NIH Grant-Award of$173,987 was received from NIH-Nat'l Inst. of Neurological
Disorders and Stroke effective September 20, 2015 through August 31, 2017. $86,244 of
funding was received in FYI 7.
CTR Advancing Translational Sciences-Award of $288,262 was received from NIH-Nat'l
Ctr Advancing Transitional Sciences effective August 14, 2015 through March 31, 2019.
$214,724 of funding was received in FY 17.
CDC Contract -Award of $228,946 was received from Antagen Pharmaceuticals, Inc.
effective September 30, 2015 through September 29, 2017. $106,585 of funding was received
in FYI 7.
UCSF Grant-Award of $675,488 was received from University of California San Francisco
effective July 16, 2016 through June 30, 2021. $229,438 of funding was received in FYI 7.
MOH Grant -An award of $406,345 was received effective December 1, 2016 through
October 31, 2018. $84,752 of funding was received in FYI 7.
5 
d. Status of existing agreements, royalties and other benefits
MassBiologics had the following major existing agreements in FYI 7.
Bristol-Meyers Squibb, formerly Medarex - a collaborative development agreement had
previously been signed April 17, 2002 with a public company (Medarex). This agreement
remains in place in support of MassBiologics' continued research.
The Materials Cooperative Research and Development Agreement (M-CRADA) that was
entered into January 30, 2004 with the CDC for Rabies was extended until January 30, 2006.
Subsequently, that agreement evolved into an Inter-institutional Agreement that was executed
in August 2005.
Merck Exclusive License Agreement April 20, 2009 for antibodies against C. Difficile. This
agreement remains in place in support of continued clinical development of MassBiologics'
proprietary CDiff antibodies.
Serum Institute of lndia License and Collaboration Agreement effective September 27, 2006.
This agreement remains in effect for the development and commercialization of a rabies
monoclonal antibody for the treatment of rabies.
Grifols Inc. - Distribution Agreement for Td vaccine in USA and Canada, effective 7/1/20 I 5,
as extended.
Voyager Therapeutics Inc. - Strategic Collaboration Agreement for development and
manufacturing of adeno associated virus (AA V) products, effective 10/20/2014.
Life Technologies Corporation - Cell Line Services License agreement effective 12/19/2014;
Commercial Production License effective 5/1/2015; authorizes use of certain materials to
support internal research and for use in services provided to external parties.
Sale of Reagents: Reagents are by-products of the major manufacturing products of
MassBiologics. MassBiologics makes these reagents available for research purposes.
e. Revenues, expenditures, assets and liabilities
On the pages that follow, please find two schedules: (I) FYI 7 Statement of Revenues and
Expenditures and Other Charges, and (2) FYI 7 Balance Sheet. This information is reviewed
as part of the University of Massachusetts annual audit and is included as part of
comprehensive financial reports made to the University of Massachusetts' Board of Trustees.
Financial activities are also reported to the Office of the State Comptroller which is still in
process for FY 2017.
When reviewing these schedules, please note:6 
• State Appropriations / DPH represents the DPH appropriated fund support of the
effort at the Biologic Laboratories of $782,276. These funds only partially support
staff and provide the supplies and equipment used in the production of vaccine which
is distributed to residents of Massachusetts without charge. The vaccine that is
provided is Tetanus-Diphtheria vaccine (Td).
• License and Royalty Fees represents such payments received for CMV-IGIV, and
monoclonal antibodies to RSV and C. difficile.
The Plant Fund is to cover the replacement of major equipment, essential facility 
improvements necessary to meet FDA and other manufacturing license requirements. This 
account includes the cumulative capitalized equipment purchases and building improvements 
and a balance of unexpended funds in reserve for planned equipment purchases and building 
improvements. In FYl 7, the plant fund continued to also be used to conclude the new facility 
expenses. 
The core activities of MassBiologics remained consistent though FYl 7. 
In calendar year 2008, the MassBiologics received its licensure from the FDA to bring its new 
production facility on line. MassBiologics continued to manufacture clinical material in the 
new facility to support its IND activities. 
The new production facility is located at the old Boston State Hospital location. This location 
was authorized by the legislature in July 2000 and opened October 2005. To support the costs 
of the new facility, Worcester City Campus Corporation borrowed in FY02 in reliance on its 
lease with the University of Massachusetts Medical School acting on behalf of MassBiologics. 
The plant fund represents payment of the lease payments supporting the bonds, as well as 
other capital costs associated with Worcester City Campus Corporation, the University of 
Massachusetts Medical School and the capital needs and operations of MassBiologics. 
Construction of Mattapan II was completed in the late spring of 2010. The project was on 
time and within budget. Mattapan II was also occupied in this timeframe. 
To support the costs of Mattapan II, Worcester City Campus Corporation borrowed $35 
million in FY07 in reliance on its lease with the University of Massachusetts Medical School 
acting on behalf of the MassBiologics. 
It was determined that MassBiologics would benefit from consolidating its operations to one 
campus by making facilities modifications to the Mattapan Campus. Modifications completed 
by June 2013 made it possible for MassBiologics to leave the Jamaica Plain Campus effective 
June 30, ending a 119 year tenancy at that campus. Commissioning and validation activities 
have been completed and the FDA has inspected and approved the manufacturing of Td 
vaccine. 
In FYl 5 it was determined that the MAB facility developed under the guidance of the UMass 
Dartmouth campus would be a better strategic fit if it were configured as a cGMP 
manufacturing resource for the development of vectored therapeutics under the operational 
control of MassBiologics. The previously identified grants (from prior year) totaling $1 OM 
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from the MLSC and MassWorks were invested in the facility located at 1240 Innovation Way 
to support the cGMP requirements of vector manufacturing. In FY 16, the initial scope of 
work was completed on time and on budget with a few areas identified for future projects. The 
facility is now positioned to develop and manufacture cGMP requirements of vector 
manufacturing; validation is ongoing. 
MassBiologics received a $2M business loan from the Greater Fall River Development in 
FYl 6. Payments will be repaid over a five year term. 
In FYl 7, the outstanding bonds related to the facilities discussed, were refinanced, thereby 
reducing the future debt service payments. 
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University of Massachusetts Biologic Laboratories 
Statement of Revenues, Expenditures and Other Changes 
For the Period July 1, 2016 Through June 30, 2017 
(Unaudited) 
CURRENT 
FUND 
APPROPRIATED 
FUNDS 
REVENUE AND OTHER ADDITIONS: 
Product Sales 
Restricted Grants and Contracts 
State Appropriations/DPH 
Royalty Fees and Interest 
Recovery of Indirect Costs 
Other Income 
Total Revenue and Other Additions 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 
Fringe Benefits 
Supplies and Services 
Depreciation 
Total Expenditures and Other Deductions 
Net lncrease/(Decrease) Before Transfers 
Nonmandatory Transfers 
Transfers 
Total Transfers 
Other Changes 
41,041,272 
8,306,975 
28,776,557 
898,294 
1,300,846 
80,323,944 
18,806,948 
5,780,941 
41,666,024 
1,542,577 
67,796,490 
12,527,454 
2,340,948 
2,340,948 
Excess of Restricted Receipts over Transfers to Revenue 
NET INCREASE(DECREASE) FOR THE YEAR 14,868,402 
Fund Balances at Beginning of Year (7/1/16) 40,597,634 
FUND BALANCES AT END OF YEAR 55,466,036 
(Unaudited) 
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782,276 
782,276 
405,732 
114,399 
262,145 
782,276 
0 
0 
TOTAL 
41,041,272 
8,306,975 
782,276 
28,776,557 
898,294 
1,300,846 
81,106,220 
19,212,680 
5,895,340 
41,928,169 
1,542,577 
68,578,766 
12,527,454 
2,340,948 
2,340,948 
14,868,402 
40,597,634 
§5_,_466,036
Assets 
Cash 
Accounts Receivable 
Inventory 
Prepaid Expenses 
Buildings & Equipment 
Other Assets 
Total Assets 
Liabilities 
Accounts Payable 
University of Massachusetts Biologic Laboratories 
Balance Sheet 
As of June 30, 2017 
(Unaudited) 
CURRENT FUND PLANT FUND 
FY17 FY17 
12,534,024 9,711,932 
13,782,025 
8,673,303 
111,683 
14,388,312 
35,101,035 24,100,244 
1,755,197 134,960 
Employee-Related Accruals 322,530 
Other Liabilities 1,522,556 
Total Liabilities 2,077,727 1,657,516 
Fund Balances 33,023,308 22,442,728 
Total Liabilities and Fund Balance 35,101,035 24,100,244 
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TOTAL 
FY17 
22,245,956 
13,782,025 
8,673,303 
111,683 
14,388,312 
59,201,279 
1,890,157 
322,530 
1,522,556 
3,735,243 
55 _,_4El§,_036 
59,201,279 
Financial Plans 
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University of Massachusetts Biologic Laboratories 
Statement of Revenues, Expenditures and Other Changes 
For the Period July 1, 2017 Through June 30, 2018 
REVENUE AND OTHER ADDITIONS: 
Product Sales 
Restricted Grants & Contracts 
State Appropriations/DPH 
Royalty Fees and Interest 
Recovery of Indirect Costs 
Other Income 
Total Revenue and Other Additions 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 
Fringe Benefits 
Supplies and Services 
Depreciation 
Total Expenditures and Other Deductions 
Net lncrease/(Decrease) Before Transfers 
Nonmandatory Transfers 
Transfers 
Total Transfers 
Other Changes 
(Unaudited) 
Excess of Restricted Receipts over Transfers to Revenue 
NET INCREASE(DECREASE) FOR THE YEAR 
Fund Balances at Beginning of Year (7/1/17) 
FUND BALANCES AT END OF YEAR 
CURRENT 
FUND 
30,893,000 
7,809,000 
18,796,000 
1,156,000 
0 
58,654,000 
19,939,000 
6,353,000 
27,210,000 
2,527,000 
56,029,000 
2,625,000 
0 
2,625,000 
53�366,036 
55,991,036 
University of Massachusetts Biologic Laboratories 
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APPROPRIATED 
FUNDS 
516,000 
516,000 
390,000 
121,000 
5,000 
0 
516,000 
0 
0 
0 
TOTAL 
30,893,000 
7,809,000 
516,000 
18,796,000 
1,156,000 
0 
59,170,000 
20,329,000 
6,474,000 
27,215,000 
2,527,000 
56,545,000 
2,625,000 
0 
2,625,000 
53,366,036 
55,991,036 
Statement of Revenues, Expenditures and Other Changes 
For the Period July 1, 2018 Through June 30, 2019 
REVENUE AND OTHER ADDITIONS: 
Product Sales 
Restricted Grants & Contracts 
State Appropriations/DPH 
Royalty Fees and Interest 
Recovery of Indirect Costs 
Other Income 
Total Revenue and Other Additions 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 
Fringe Benefits 
Supplies and Services 
Depreciation 
Total Expenditures and Other Deductions 
Net lncrease/(Decrease) Before Transfers 
Nonmandatory Transfers 
Transfers 
Total Transfers 
Other Changes 
Excess of Restricted Receipts over Transfers to Revenue 
NET INCREASE(DECREASE) FOR THE YEAR 
Fund Balances at Beginning of Year (7/1/18) 
FUND BALANCES AT END OF YEAR 
(Unaudited) 
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CURRENT 
FUND 
32,400,000 
7,808,000 
18,796,000 
1,156,000 
(400,000) 
59,760,000 
20,299,000 
6,468,000 
27,836,000 
2,400,000 
57,003,000 
2,757,000 
0 
2,757,000 
55,991,036 
58,748,036 
APPROPRIATED 
FUNDS 
516,000 
TOTAL 
32,400,000 
7,808,000 
516,000 
18,796,000 
1,156,000 
(400,000) 
516,000 60,276,000 
390,000 20,689,000 
121,000 6,589,000 
5,000 27,841,000 
0 2,400,000 
516,000 57,519,000 
0 2,757,000 
0 0 
2,757,000 
55,99Ll)�6_ 
0 58,748,036 
University of Massachusetts Biologic Laboratories 
Statement of Revenues, Expenditures and Other Changes 
For the Period July 1, 2019 Through June 30, 2020 
(Unaudited) 
CURRENT 
FUND 
APPROPRIATED 
FUNDS 
REVENUE AND OTHER ADDITIONS: 
Product Sales 
Restricted Grants & Contracts 
State Appropriations/DPH 
Royalty Fees and Interest 
Recovery of Indirect Costs 
Other Income 
Total Revenue and Other Additions 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 
Fringe Benefits 
Supplies and Services 
Depreciation 
Total Expenditures and Other Deductions 
Net lncrease/(Decrease) Before Transfers 
Nonmandatory Transfers 
Transfers 
Total Transfers 
Other Changes 
Excess of Restricted Receipts over Transfers to Revenue 
NET INCREASE(DECREASE) FOR THE YEAR 
Fund Balances at Beginning of Year (7/1/19) 
FUND BALANCES AT END OF YEAR 
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33,532,000 
7,808,000 
18,796,000 
1,156,000 
(400,000) 
60,892,000 
20,683,000 
6,590,000 
28,252,000 
2,472,000 
57,997,000 
2,895,000 
0 
2,895,000 
58,748,036 
61,643,036 
516,000 
516,000 
390,000 
121,000 
5,000 
0 
516,000 
0 
0 
0 
TOTAL 
33,532,000 
7,808,000 
516,000 
18,796,000 
1,156,000 
(400,000) 
61,408,000 
21, 073,000 
6,711,000 
28,257,000 
2,472,000 
58,513,000 
2,895,000 
0 
2,895,000 
58,748,036 
61,643,036 
